Genotype-specific neoplastic risk profiles in patients with VHL disease
Endocrine-Related Cancer · 01.05.2025 · 32 (5)
DOI: 10.1530/erc-24-0260 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Endocrine-Related Cancer, online erschienen am 09.04.2025. Verfasst von Athina Ganner und 59 weiteren Autor:innen. Hauptthemen laut MEDLINE: von Hippel-Lindau Disease, Von Hippel-Lindau Tumor Suppressor Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Fundação de Amparo à Pesquisa do Estado de São Paulo, Fondo Nacional de Desarrollo Científico y Tecnológico.
Abstract (Originalsprache)
Hereditary tumor predisposition syndromes pose a challenge for early detection and timely treatment of tumors. In von Hippel–Lindau disease, desirable personalized surveillance programs are lacking due to insufficient data on genotype-specific risk profiles of individual mutations. To describe neoplastic risk profiles for carriers of pathogenic and likely pathogenic VHL germline mutations, our observational study recruited 1,350 participants from 40 centers worldwide. 432 different VHL germline mutations were observed, with p.Asn78Ser, p.Arg161Ter, p.Arg161Gln, p.Arg167Gln, p.Arg167Trp and p.Tyr98His being the six most frequent, occurring in a total of 493 carriers (36.5%) and in ≥30 patients each. Age-related penetrance risks for retinal hemangioblastoma, central nervous system hemangioblastoma, renal cell carcinoma, pancreatic neuroendocrine tumors and pheochromocytoma/paraganglioma in carriers of the most frequent VHL mutations were assessed. In addition, the number of organs affected, the frequency of surgery and the outcome are reported. Pairwise comparisons of the age-dependent tumor penetrance of these six mutations showed that 47 out of 90 pairs were significantly different. The most significant associations were found in p.Tyr98His (n = 19), followed by p.Arg161Ter (n = 10). All pairwise comparisons of mutations affecting different codons showed at least one significant (P < 0.05) difference, except for p.Asn78Ser vs p.Arg161Ter. Thus, tumor risk varied by VHL mutation type and location, but did not differ between the truncating mutation p.Arg161Ter and the missense mutation p.Asn78Ser. Our study demonstrates the importance of mutation-specific phenotype prediction. With appropriate validation, the data have important implications for risk assessment and decision making in tumor prevention for carriers of the respective VHL mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Athina Ganner, Peggy Sekula, Madson Q Almeida
Förderung
- Deutsche Forschungsgemeinschaft
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Fondo Nacional de Desarrollo Científico y Tecnológico
- NIHR Cambridge Biomedical Research Centre
Zitieren
APA
Ganner, A., Ferrara, A. M., Sekula, P., Schiavi, F., Joo, J. H., Sanso, G., Almeida, M. Q., Knoblauch, A. L., Gizaw, C. J., Krzystolik, K., Astheimer, S. C., Achatz, M. I., Vieites, A., Donegan, D., Hundsberger, T., Lubinski, J., Yildirim Simsir, I., Bandgar, T., Hasse-Lazar, K., …, & Bucher, F. (2025). Genotype-specific neoplastic risk profiles in patients with VHL disease. Endocrine-Related Cancer, 32(5). https://doi.org/10.1530/erc-24-0260
Vancouver
Ganner A, Ferrara AM, Sekula P, Schiavi F, Joo JH, Sanso G, et al. Genotype-specific neoplastic risk profiles in patients with VHL disease. Endocrine-Related Cancer. 2025;32(5). doi:10.1530/erc-24-0260
BibTeX
@article{Ganner2025,
author = {Ganner, Athina and Ferrara, Alfonso Massimiliano and Sekula, Peggy and Schiavi, Francesca and Joo, Julia H and Sanso, Gabriela and Almeida, Madson Q and Knoblauch, Anna Laura and Gizaw, Christine Julia and Krzystolik, Karol and Astheimer, Sophie Charlotte and Achatz, Maria Isabel and Vieites, Ana and Donegan, Diane and Hundsberger, Thomas and Lubinski, Jan and Yildirim Simsir, Ilgin and Bandgar, Tushar and Hasse-Lazar, Kornelia and Pawlaczek, Agnieszka and Zandee, Wouter and Yu, Kai and Kater, Claudio E and Rostomyan, Liliya and Qi, Xiao-Ping and Deutschbein, Timo and Remde, Hanna and Dallagnol, Tabatha Nakakogue and Yukina, Marina and Baudrand, Rene and Andreescu, Corina E and Kunavisarut, Tada and Ishak, Nur Diana and Le Guillou Horn, Xavier and Shutler, Gemma and Jovanovic, Milan and Pęczkowska, Mariola and Calissendorff, Jan and Circosta, Francesco and Bugalho, Maria João and Corssmit, Eleonora P M and Gimm, Oliver and Quinkler, Marcus and Goldmann, Andrea and Watutantrige Fernando, Sara and Zovato, Stefania and Santana, Lucas S and Freitas-Castro, Felipe and Rothermundt, Christian and Zimmermann, Josa and Durmaz, Asude and Aykut, Ayca and Vroonen, Laurent and Krauss, Tobias and Taschner, Christian and Ruf, Juri and Klingler, Jan-Helge and Gläsker, Sven and Lang, Stefan and Bucher, Felicitas},
title = {Genotype-specific neoplastic risk profiles in patients with VHL disease},
journal = {Endocrine-Related Cancer},
year = {2025},
volume = {32},
number = {5},
doi = {10.1530/erc-24-0260}
}
EUVIMED